Erin Wilson
Stock Analyst at Morgan Stanley
(1.79)
# 3,127
Out of 4,761 analysts
19
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $46 | $31.71 | +45.06% | 4 | Jul 10, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $190.43 | +284.39% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $163.02 | +136.17% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $191.04 | +38.71% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $340.22 | -39.74% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $201.39 | +24.14% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $11.02 | +244.83% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $16.46 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $532.55 | -35.97% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.64 | +3,192.68% | 4 | Nov 14, 2017 |
Rapid7
Jul 10, 2024
Maintains: Equal-Weight
Price Target: $46
Current: $31.71
Upside: +45.06%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $190.43
Upside: +284.39%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $163.02
Upside: +136.17%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $191.04
Upside: +38.71%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $340.22
Upside: -39.74%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $201.39
Upside: +24.14%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $11.02
Upside: +244.83%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $16.46
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $532.55
Upside: -35.97%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.64
Upside: +3,192.68%